Johnson & Johnson (NYSE:JNJ) is the leader in the prostate cancer hormonal therapy market, with Zytiga sales of $3.5 billion in 2018. Other key drugs include Astellas’ Xtandi, and AbbVie’s Lupron.

Cipla is introducing leuprolide acetate injection depot, 22.5 mg, which is the generic of AbbVie’s Lupron Depot. It is indicated for palliative treatment of advanced prostate cancer. Leuprolide ...

ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...

Leuprolide acetate for injection is used to treat the symptoms associated with advanced prostate cancer by way of palliative treatment of advanced prostatic cancer. Aurobindo’s subsidiary, Eugia ...

More than 10,000 adverse event reports complaining about the side effects of a commonly used drug called Lupron have been filed with the Food and Drug Administration, according to a recent report by ...